Skip to content

A Real-World Study on Zaogong Erteng Decoction in the Treatment of Endometritis Complicated with Infertility

A Real-World Study on Zaogong Erteng Decoction in the Treatment of Endometritis Complicated with Infertility

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000718
Enrollment
Unknown
Registered
2025-04-13
Start date
2025-03-27
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometritis complicated with infertility

Interventions

control group:Take Moxifloxacin Hydrochloride Tablets orally
treatment group:Take Moxifloxacin Hydrochloride Tablets orally and take Zaogong Erteng Decoction

Sponsors

Affiliated Hospital of Jining Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 42 Years

Inclusion criteria

Inclusion criteria: (1) Meeting the diagnostic criteria for chronic endometritis in the 9th edition of "Obstetrics and Gynecology", and having evidence of positive hysteroscopy and histopathological examination results (including HE staining and CD138 immunohistochemistry); (2) Receiving assisted reproductive technology for infertility treatment in our hospital; (3) Meeting the traditional Chinese medicine syndrome differentiation criteria of damp-heat and blood stasis; (4) Aged between 20 and 42 years old; (5) Being informed about the content of this study, voluntarily participating, and signing the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of allergy to the drugs used in this study; (2) Patients complicated with diseases such as endometrial tuberculosis, endometriosis, endometrial cancer, acute genital tract infections, etc., as well as those with congenital malformations of the reproductive system; (3) Patients with malignant tumors, severe diseases of the hematopoietic system, circulatory system, and immune system, sexually transmitted diseases, severe liver and kidney insufficiency, and those with infections in other parts; (4) Patients with a history of treatment with antibiotics and immunosuppressants within the past 1 month; (5) Subjects who are currently receiving treatment with other traditional Chinese medicines or participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
The recovery status of the lesions under hysteroscopy;Histopathological changes;

Secondary

MeasureTime frame
Changes in peripheral blood inflammatory factors;Safety examination;Evaluation of Traditional Chinese Medicine Syndrome Scores;Pregnancy outcome;

Countries

China

Contacts

Public ContactAijun Yang

Affiliated Hospital of Jining Medical University

yajlws@126.com18678766779

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026